S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY

Detalles Bibliográficos
Autores principales: Heeney1, Matthew, Rees, David, de Montalembert, Mariane, Odame, Isaac, Wali, Yasser, Sayyed, Sarfaraz, Shanmuganathan Muthusamy, Velusamy, Mendonza, Anisha E., Nassin, Michele, Keefe, Deborah, Kanter, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428338/
http://dx.doi.org/10.1097/01.HS9.0000967980.32472.94

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428338/
http://dx.doi.org/10.1097/01.HS9.0000967980.32472.94

Ejemplares similares